Autoimmune hepatitis is not curable in the traditional sense. It is a chronic condition that can be controlled, often very effectively, but the underlying immune dysfunction that drives it does not go away. The realistic goal of treatment is remission, a state where liver inflammation quiets down and blood markers return to normal. Most people with autoimmune hepatitis need some form of immunosuppressive medication for years, and many need it for life.
What Remission Actually Means
When doctors talk about remission in autoimmune hepatitis, they mean two things are happening. First, blood levels of liver enzymes (transaminases) and a specific immune protein called immunoglobulin G (IgG) have returned to normal. This is called biochemical remission, and it’s the primary target doctors track because it can be checked with routine blood draws. Second, and ideally, a liver biopsy shows minimal or no active inflammation, scored below 4 on an 18-point scale used by pathologists.
Remission is not the same as a cure. Your immune system still carries the tendency to attack your liver. Treatment suppresses that attack, and remission means the suppression is working. Think of it like controlling high blood pressure with medication: the numbers look good, but the underlying condition hasn’t disappeared.
How Treatment Works
First-line treatment combines a corticosteroid (typically prednisone or prednisolone) with an immune-suppressing drug called azathioprine. You start on a higher dose of the steroid, usually 40 to 60 mg per day for adults, then taper it down over four to eight weeks as your liver enzymes improve. The goal is to get you to the lowest effective dose, or ideally off steroids entirely, while azathioprine keeps things stable long-term.
Most people respond well to this combination. For those who don’t, or who can’t tolerate azathioprine, second-line options exist. Mycophenolate mofetil achieves complete remission in roughly 13 to 34% of patients who failed first-line therapy, though one study reported rates as high as 57%. Tacrolimus, another immune suppressant, has shown remission rates ranging from 20 to 92% in small studies, though that wide range reflects how limited the data still is. A large clinical trial comparing these two drugs head-to-head is underway.
Can You Ever Stop Medication?
This is the question most people really want answered, and the honest answer is: probably not, though some people can. Guidelines recommend staying on immunosuppressive therapy for at least two years after your blood markers fully normalize. Before stopping, a liver biopsy is strongly recommended to confirm the inflammation is truly gone, not just hiding behind normal blood results.
Even with that careful approach, roughly two-thirds of patients relapse after stopping medication. In one study, 67% of patients who withdrew from treatment relapsed within an average of 19 months, and most of those relapses happened within the first year. Only about one in three patients successfully stayed off medication without the disease flaring back up. When relapse happens, 42% of patients experience it as a sudden, acute hepatitis attack rather than a slow creep.
Because of these odds, many gastroenterologists recommend indefinite low-dose maintenance therapy rather than attempting withdrawal. The calculus is simple: the risks of a relapse (which can cause further liver damage) generally outweigh the inconvenience and side effects of staying on a low dose of medication.
What Happens If It’s Not Well Controlled
The stakes of poor control are real. Among patients who already had cirrhosis from autoimmune hepatitis, those whose liver enzymes did not normalize on treatment fared significantly worse: 75% experienced serious complications like fluid buildup in the abdomen, internal bleeding from swollen veins, or liver failure. By contrast, only 15% of patients who achieved normal enzyme levels on treatment had those kinds of events.
Over the long term, liver-related death or the need for a transplant occurs in about 11% of patients at 10 years and 21% at 20 years. All-cause mortality (including non-liver causes) is higher, around 24% at 10 years and 51% at 20 years, though that figure includes patients diagnosed at older ages who may die of unrelated causes. The key takeaway is that disease progression can continue even beyond 20 years, which is why ongoing monitoring matters even when you feel fine.
Liver Transplant as a Last Resort
For the small percentage of patients who develop end-stage liver disease despite treatment, transplantation is an option with good outcomes. One-year survival after transplant for autoimmune hepatitis is approximately 90%, and five-year survival is around 80%.
There is a catch, though. Autoimmune hepatitis can come back in the new liver. Recurrence rates range from 16 to 43%, which makes sense given that the problem is the immune system, not the liver itself. The good news is that recurrence in a transplanted liver is usually manageable. Fewer than 5% of patients need a second transplant because of it.
Living With a Chronic but Controllable Disease
The practical reality for most people with autoimmune hepatitis is a life that looks largely normal, punctuated by regular blood tests and daily medication. You’ll typically have liver enzymes and IgG levels checked every few months once stable, and your doctor may recommend periodic imaging or biopsies depending on how things progress. The medications can carry side effects, particularly the steroids (weight gain, bone thinning, mood changes), which is why the treatment strategy focuses on minimizing steroid use over time.
The difference between a good outcome and a poor one comes down mostly to whether the disease is caught early and whether treatment achieves full biochemical remission. Partial improvement is not enough. Patients whose enzyme levels normalize do dramatically better than those with persistent, even mildly elevated, inflammation. If your current regimen isn’t getting your numbers to normal, that’s a conversation worth having with your specialist about switching or adjusting therapy.